NCT05797376View on ClinicalTrials.gov

Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation

PHASE4CompletedINTERVENTIONAL
Enrollment

92

Participants

Timeline

Start Date

August 24, 2021

Primary Completion Date

November 12, 2024

Study Completion Date

December 5, 2024

Conditions
Atherosclerosis of ArteryCoronary Artery DiseasePeripheral Arterial DiseaseCarotid Stenosis
Interventions
DRUG

Rivaroxaban 2.5mg

patients are prescribed aspirin at a daily dose of 100mg and Rivaroxaban (2.5 mg twice a day)

Trial Locations (1)

05505

Asan Medical Center, Seoul

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Asan Medical Center

OTHER

NCT05797376 - Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation | Biotech Hunter | Biotech Hunter